ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)
Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –
ADMA Biologics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
ADMA Biologics's total debt was $195.86M at Sep 30, 2026. For fiscal 2025 it was $72.14M, down 0.3% from the year before. Over ten years it grew 34.3% a year on average. The highest annual figure on record is $92.97M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.14M | -0.3% |
| FY2024 | Dec 31, 2024 | $72.34M | -22.2% |
| FY2020 | Dec 31, 2020 | $92.97M | +36.1% |
| FY2019 | Dec 31, 2019 | $68.29M | +158.3% |
| FY2018 | Dec 31, 2018 | $26.44M | +4.2% |
| FY2017 | Dec 31, 2017 | $25.37M | +105.9% |
| FY2016 | Dec 31, 2016 | $12.32M | -13.5% |
| FY2015 | Dec 31, 2015 | $14.25M | -2.2% |
| FY2014 | Dec 31, 2014 | $14.57M | +199.4% |
| FY2013 | Dec 31, 2013 | $4.87M | +28.9% |
| FY2012 | Dec 31, 2012 | $3.77M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $195.86M | +170.4% |
| Q2 FY2026 | Jun 30, 2026 | $196.59M | +171.8% |
| Q1 FY2026 | Mar 31, 2026 | $196.87M | +110.7% |
| Q4 FY2025 | Dec 31, 2025 | $72.14M | -22.4% |
| Q3 FY2025 | Sep 30, 2025 | $72.43M | -11.8% |
| Q4 FY2024 | Dec 31, 2024 | $72.34M | -11.4% |
| Q1 FY2021 | Mar 31, 2021 | $93.41M | +15.0% |
| Q4 FY2020 | Dec 31, 2020 | $92.97M | +36.1% |
| Q3 FY2020 | Sep 30, 2020 | $82.11M | +21.0% |
| Q2 FY2020 | Jun 30, 2020 | $81.65M | +21.0% |
| Q1 FY2020 | Mar 31, 2020 | $81.21M | +98.6% |
| Q4 FY2019 | Dec 31, 2019 | $68.29M | +158.3% |
| Q3 FY2019 | Sep 30, 2019 | $67.84M | +159.4% |
| Q2 FY2019 | Jun 30, 2019 | $67.47M | +160.7% |
| Q1 FY2019 | Mar 31, 2019 | $40.89M | +59.6% |
| Q4 FY2018 | Dec 31, 2018 | $26.44M | +4.2% |
| Q3 FY2018 | Sep 30, 2018 | $26.15M | +79.9% |
| Q2 FY2018 | Jun 30, 2018 | $25.88M | +176.5% |
| Q1 FY2018 | Mar 31, 2018 | $25.62M | +136.2% |
| Q4 FY2017 | Dec 31, 2017 | $25.37M | +105.9% |
| Q3 FY2017 | Sep 30, 2017 | $14.53M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.36M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.32M | – |
See a number that looks wrong?